Aro Biotherapeutics

CIC Philadelphia

3675 Market Street, Suite 200

Philadelphia, PA 19104

Email: info@arobiotx.com 

Aro LinkedIn

© 2018 Aro Biotherapeutics Company. All Rights Reserved.

Liz McKee Anderson

Liz McKee Anderson is a senior executive in the pharmaceutical and biotech sector and serves as the Independent Board Director for REVOLUTION Medicines, Inc., Context Therapeutics, and Aro Biotherapeutics, Board Director for Bavarian Nordic A/S, a Board Director for Huntsworth Plc, a Board Member of Insmed, Inc., and as a Member of the Executive Committee for The Wistar Institute. Until her retirement from Johnson & Johnson, she served as the Worldwide Vice President (WWVP) and Commercial Leader in the IDV Global Commercial Strategy Organization, leading strategy, global commercialization and market access for Respiratory Infections, HIV, STI and Bacterial Pathogens and championed acquisition and business cases for more than 25 assets. In a prior role as the WWVP Vaccines, Liz partnered to develop and execute the first Johnson & Johnson Global Vaccines Strategy, played a key role in the acquisition of Crucell and established capabilities in the field of prevention. Previously, she served as the WWVP, Immunology, Global Strategic Marketing where she was responsible for the therapeutic area strategy and commercial pipeline development of a large portfolio of small and large molecules. Liz also served for five years as the Vice President/GM of Wyeth Vaccines, leading a team of over 400, launching PREVNAR® and building a $1 billion, high growth business. Liz received an MBA from Loyola University Maryland and a BEng from Rutgers University.

Susan Dillon, PhD

Co-founder, President and Chief Executive Officer, Aro Biotherapeutics

 

Sue Dillon, PhD, brings 30 years of experience in executive leadership roles at pharmaceutical and biotech companies to Aro Biotherapeutics. During her more than 16 year career at Johnson & Johnson, Sue led global Immunology R&D, and achieved numerous regulatory approvals for innovative antibody products for autoimmune diseases including REMICADE®, SIMPONI®, STELARA® and TREMFYA®. She also built a robust Immunology development portfolio through internal discovery and external licensing, and championed research into the emerging areas of the microbiome and immune repertoire profiling. Multi-disciplinary teams under Sue’s leadership were twice recognized with the Prix Galien Award for PROMACTA® and STELARA®, each first-in-class medicines. Sue received her PhD in Immunology from Thomas Jefferson University in Philadelphia and completed a postdoctoral fellowship in Immunology at Duke University. She was named by FierceBiotech as one of the Top Women in Biotech in 2013.

Karyn O’Neil, PhD

Co-founder and Chief Scientific Officer, Aro Biotherapeutics

 

Karyn O’Neil has more than 30 years of experience in peptide, antibody and protein engineering. As the Venture Leader for Centyrex, a Johnson & Johnson Venture, Karyn focused on designer protein platform technologies. She is co-inventor on the Centyrin patents and has led the team advancing the Centyrin platform since its inception. She joined Centocor/Johnson & Johnson in 2001 where, prior to working on Centyrins, she held positions of increasing responsibility, ultimately becoming a Director of Antibody Therapeutics. There she played a leadership role in the discovery and optimization of multiple clinical candidates. Prior to Johnson & Johnson, Karyn was in the Applied Biotechnologies group at DuPont Pharmaceuticals. Karyn received her PhD from the University of Pennsylvania where she focused on protein engineering and protein biophysics. She has authored more than 55 publications and holds over 30 patents. Karyn also serves as an editor for Protein Engineering, Design and Selection.  

Bruce Peacock

 

During his more than 35 year career in biotechnology, Bruce Peacock has held numerous senior leadership positions, including President and Chief Executive Officer of Adolor Corporation, Alba Therapeutics and Orthovita, Inc., and Chief Financial Officer (CFO) and Business Officer of Ophthotech. For over 10 years, he served as Venture Partner with SV Life Sciences Health Venture. Previously, he was Executive Vice President and Chief Operating Officer of Cephalon Inc. and prior to this, he was CFO at Centocor, Inc. He is a member of the Board of Directors of Carisma Therapeutics, invisible Sentinel, Ocular Therapeutics, PanOptica and Windtree Therapeutics. Bruce holds a BA in Business Administration from Villanova University.